Microbio Co., Ltd. (TPEX:4128)

Taiwan · Delayed Price · Currency is TWD

15.05

+0.30 (2.03%)

Jun 18, 2026, 1:30 PM CST

-39.92% (1Y)

Market Cap	8.85B -38.1%
Revenue (ttm)	1.94B +9.8%
Net Income	-691.94M
EPS	-1.18
Shares Out	588.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	858,936
Open	14.75
Previous Close	14.75
Day's Range	14.75 - 15.05
52-Week Range	14.20 - 27.50
Beta	0.44
Analysts	n/a
Price Target	21.58 (+43.39%)
Earnings Date	Aug 10, 2026

About Microbio

Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia in women before menopause and relieved dysmenorrhea. It also involved in the trading of organic foods; sale of beverages; provision of technology development, transfer, and consultation services; and publishing of magazine, as well as offers business consulting services. Mic... [Read more]

Industry Packaged Foods

Sector Consumer Staples

Founded 2000

Country Taiwan

Stock Exchange Taipei Exchange

Ticker Symbol 4128

Full Company Profile

Financial Performance

In 2025, Microbio's revenue was 1.89 billion, an increase of 9.94% compared to the previous year's 1.72 billion. Losses were -757.75 million, -31.16% less than in 2024.

Financial Statements